Serum Institute of India (SII) News

"The first consignment from the Pune facility of Serum Institute of India was scheduled to leave for Nepal today. However, due to some reason, it has been delayed by two to three days," said SII sources.

"I am against the mixing of two different vaccines. There is no need to mix two different vaccines," said Cyrus Poonawalla. He further stated that the efficacy of this approach has not been proven in field trials involving thousands of participants.

Poonawala said he is hopeful that for adults Covovax will be launched in October, depending on DCGI approvals. It will be a two-dose vaccine and the price will be decided at the time of launch, he added. Poonawalla met Home Minister Amit Shah in Parliament and the meeting between the two lasted for 30 minutes.

On Saturday, France lifted travel restrictions for fully vaccinated travellers. Indian government has been pushing European Union member countries to recognise both Covishield and Covaxin in order to ease travel for the people

EMA has approved only four vaccines namely, Comirnaty of Pfizer/BioNTech, Moderna's Spikevax, Vaxzervria by AstraZeneca-Oxford and Johnson & Johnson's Janssen. The SII’s CEO Adar Poonawalla had earlier said that the company is confident of receiving approval from the EMA.

The CEO of Serum Institute of India (SII) Adar Poonawalla on Monday assured the people of the nation that the issue is being with at the highest level. The statement comes amid the reports of the European Union’s new concept of Green Pass is doing rounds in media.

Serum Institute plans to start clinical trials of the Novavax shot for children in July. ANI reported. "This vaccine is very safe and highly effective. It`ll be produced in India," Centre said about Covavax.

The Centre on Sunday (May 30, 2021) said that it targets to procure 20-25 crore coronavirus vaccine doses by July-end, and 30 crore doses in August-September. The SII officials in a recent letter addressed to Home Minister Amit Shah said that their employees have been working round the clock in spite of the challenges that the pandemic presents.

The executive director of SII, Suresh Jadhav on Friday alleged that the central government widened the COVID-19 vaccination drive without into account the available stock of vaccines. "India should have followed the WHO guidelines and prioritised vaccination accordingly," said Suresh Jadhav.

Poonawalla said that it will take another two to three years for the entire world population to get fully vaccinated He also said that "a vaccination drive for such a large population cannot be completed within 2-3 months" The serum has delivered more than 200 million doses

As per BSE block deal data, Poonawalla sold 31,57,034 scrips he held in the firm at a price of Rs 373.85 per share.

Bharat Biotech International Ltd will soon start manufacturing Covid-19 vaccines in Pune The state would also request the BBIL to give priority to supply vaccines to Maharashtra after fulfilling its commitments to the Centre Currently, the government-owned BBIL is one of the two Indian companies manufacturing the Covaxin and Covishield vaccines

Bill Gates in an interview with Sky News was asked if it would be possible to change the intellectual property law Bill Gates refused to share vaccine formula Bill Gates faces heat from global community for this statement

COVAX has so far received 17.7 million AstraZeneca doses from the SII The SII has already delayed shipments of the AstraZeneca drug to Brazil, Britain, Morocco and Saudi Arabia With 11.7 million cases, India has reported the highest number of coronavirus infections after the United States and Brazil

The Centre also clarified that the above instruction is only for Covishield and not Bharat Biotech’s Covaxin. "This decision of revised time interval between two doses is applicable ONLY to COVISHIELD and NOT to COVAXIN Vaccine," the government stated.

Nepal has expedited preparations to start inoculating elderly and most vulnerable age groups from next month as it received a batch of COVID-19 vaccines purchased from India. A batch of one million Covishield vaccines developed by the Serum Institute of India (SII) was delivered on Sunday (February 21) via an Air India flight.

The approval for conducting phase 2 and 3 clinical trials by the SII was granted by DCGI Dr V G Somani late Sunday night. Currently, phase 2 and 3 clinical trials of the Oxford vaccine candidate is going on in the United Kingdom, phase 3 clinical trial in Brazil and phase 1 and 2 clinical trials in South Africa. The SII, which has partnered with AstraZeneca, for manufacturing the Oxford vaccine candidate for COVID-19 had submitted its first application to the DCGI on July 25.